Lee Woohyung, Song Ki Byung, Hong Sarang, Park Yejong, Kwak Bong Jun, Jun Eunsung, Hwang Dae Wook, Kim Sehee, Lee Jae Hoon, Kim Song Cheol
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Surg Endosc. 2023 Feb;37(2):881-890. doi: 10.1007/s00464-022-09533-y. Epub 2022 Aug 26.
Minimally invasive pancreaticoduodenectomy (MIPD) has been extended to periampullary cancers, but the oncologic outcome of MIPD for distal bile duct cancer (DBDC) has not been confirmed yet.
Patients who underwent pancreaticoduodenectomy (PD) for DBDC of stage I-IIb from 2015 to 2019 at a tertiary referral center were identified and divided into open PD (OPD) and MIPD groups, the latter including laparoscopic and robotic procedures. Survival was compared between the two groups after inverse probability of treatment weighting (IPTW) using predetermined factors, and exploratory mediation analysis was performed using surgery-derived outcomes.
MIPD (n = 81) group had more female patients (46.9% vs 31.6%, p = 0.011) and longer operation time (366.2 min vs. 279.1 min, p < 0.001) than the OPD (n = 288) group before IPTW. Otherwise, intraoperative and immediate postoperative outcomes were comparable between the two groups. In oncologic outcomes, MIPD group showed comparable 3-year overall survival (78.2% vs 75.0%, p = 0.062) and recurrence-free survival (51.2% vs 53.4%, p = 0.871) rates with OPD group before IPTW, and MIPD was not related with survival (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.29-1.26, p = 0.18) and recurrence (HR 1.01, 95% CI 0.67-1.53, p = 0.949) after IPTW with consideration of potential mediators. Sensitivity analysis using propensity score matching also showed similar results for survival (HR 0.68, 95% CI 0.32-1.44, p = 0.312) and recurrence (HR 1.12, 95% CI 0.67-1.88, p = 0.653).
MIPD and OPD groups showed similar postoperative and oncologic outcomes. MIPD could be a considerable treatment option without oncological compromise in high-volume centers.
微创胰十二指肠切除术(MIPD)已扩展至壶腹周围癌,但MIPD治疗远端胆管癌(DBDC)的肿瘤学结局尚未得到证实。
确定2015年至2019年在一家三级转诊中心因I-IIb期DBDC接受胰十二指肠切除术(PD)的患者,并分为开放PD(OPD)组和MIPD组,后者包括腹腔镜手术和机器人手术。使用预定因素进行治疗权重逆概率(IPTW)后,比较两组的生存率,并使用手术衍生结局进行探索性中介分析。
在IPTW之前,MIPD组(n = 81)比OPD组(n = 288)有更多女性患者(46.9%对31.6%,p = 0.011)和更长的手术时间(366.2分钟对279.1分钟,p < 0.001)。否则,两组的术中及术后即刻结局相当。在肿瘤学结局方面,MIPD组在IPTW之前与OPD组的3年总生存率(78.2%对75.0%,p = 0.062)和无复发生存率(51.2%对53.4%,p = 0.871)相当,并且在考虑潜在中介因素的IPTW后,MIPD与生存率(风险比[HR] 0.61,95%置信区间[CI] 0.29 - 1.26,p = 0.18)和复发率(HR 1.01,95% CI 0.67 - 1.53,p = 0.949)无关。使用倾向评分匹配的敏感性分析在生存率(HR 0.68,95% CI 0.32 - 1.44,p = 0.312)和复发率(HR 1.12,95% CI 0.67 - 1.88,p = 0.653)方面也显示了相似的结果。
MIPD组和OPD组显示出相似的术后及肿瘤学结局。在高容量中心,MIPD可能是一种在不影响肿瘤学效果的情况下相当不错的治疗选择。